Dermatology practice consolidation: a guide to platforms and owner equity

Executive summary

Private equity is one source of capital and operating support for dermatology practices, and consolidation has created more potential buyers and complicated deal structures. A typical transaction places an established practice inside a larger platform, then pursues growth through acquisitions, new offices and centralized services. An owner may receive cash, retain a minority economic interest and remain employed while exchanging some local autonomy for shared systems and investor oversight. Each element needs separate evaluation.

The owner's central task is to understand what is being sold, what is being retained, and who controls the decisions that shape future value. A purchase price expressed as a multiple of earnings does not tell you the amount of cash at closing. It does not establish the value of rollover equity, guarantee a second sale, or settle what compensation and clinical governance will look like after closing. The signed agreements, capital structure, accounting definitions and management arrangements determine those outcomes.

The available research describes acquisition activity and selected practice outcomes, but it does not provide a reliable universal valuation multiple or prove that one ownership model is best for every practice. Studies use different samples and definitions. Owners can use the findings as context while grounding a decision in their own normalized financials and transaction documents.

A disciplined process begins before an offer arrives. Reconcile earnings, map the practice's entities and contracts, clarify shareholder priorities and build a credible alternative to selling. Compare bids on net cash, contingent value and work obligations. Have independent counsel review the structure. An attractive transaction can still be a poor fit if owners cannot explain how value flows through the platform or what happens when the relationship changes.

Key figures

The studies above use different definitions and observation windows. Their numbers should not be added together. They describe documented research samples, not a census of every transaction.

Analysis

1. Why dermatology attracts platform buyers

A platform buyer generally looks for a practice with enough scale and capable clinicians to anchor a broader organization. Dermatology combines recurring medical visits with procedures and surgery across multiple sites. That mix can support centralized billing and revenue-cycle teams when workflows are consistent. A practice with reliable access and clean operational data may be valuable even if it is not the largest group in its region.

The platform thesis is more than "buy clinics and cut costs." Buyers may expect to recruit physicians, extend hours, open offices, improve scheduling, standardize administrative work, negotiate contracts or add complementary services. Those initiatives require capital and local execution. Owners should ask which changes have actually been implemented at the buyer's existing practices, what resources are dedicated to them, and how results are measured. A presentation describing scale economies is a hypothesis until the buyer can show operating evidence.

A seller should also ask whether the business plan depends on increasing physician capacity or simply increasing visit volume. Growth can require more clinicians, rooms, equipment, support staff, working capital and payer contracting. If the model assumes rapid hiring in a constrained labor market, pressure may fall on existing owners to absorb schedules or maintain production while new capacity develops. Discuss recruiting costs and ramp periods before treating projected growth as transaction value.

2. Platform and add-on economics

The platform is the initial operating company or group around which the buyer intends to consolidate other practices. An add-on is a later acquisition integrated into that platform. A founder selling to the platform may receive a different valuation, governance position and rollover opportunity from an owner joining later. The distinction matters because a platform owner may carry responsibility for integration and growth initiatives. An add-on owner may be asked to adopt systems already selected by the platform.

The platform's return case can combine earnings growth, new sites and debt financing. Each part carries execution risk. Add-ons may increase scale while also adding integration expense or physician departures. Growth by acquisition does not automatically create value for each seller. Ask how add-ons are funded, whether platform equity is diluted, and whether acquired earnings enter the metric used for your rollover.

An illustrative example: a platform reports $10 million of adjusted earnings before an add-on and pays $5 million for a smaller practice said to contribute $1 million of similar earnings. If integration, debt service, new support costs or physician turnover reduce the acquired contribution, headline scale can rise while distributable cash does not. The figures are illustrative only. Owners should request a bridge from reported earnings to cash available after interest, capital spending, taxes, working capital and contractual obligations.

Ask whether seller proceeds use standalone or platform earnings. If the offer includes a "synergy" adjustment, identify the savings opportunity, who must implement it, and whether the seller shares in the result. A multiple applied to an adjusted number is useful only when the adjustment has clear support and consistent application.

3. MSO structures and the clinical entity

Many physician transactions use a management services organization, or MSO, alongside a professional entity that provides clinical services. The professional corporation or other permitted clinical entity remains responsible for medical practice under applicable state law. The MSO may provide billing and administrative services under a management services agreement. Investors may own the MSO while physicians retain ownership or specified control of the professional entity.

The arrangement's legal labels do not answer the practical questions. Map the ownership chain, the entities that employ staff, who owns equipment and records, who controls the bank accounts, who sets budgets, and which entity carries each liability. Identify who can hire or terminate the practice administrator, approve compensation plans, change service locations, select vendors, or direct the use of clinical space. Confirm how the MSO fee is calculated and what services it covers. An agreement that assigns nearly all economics to the MSO while leaving the clinical entity with fixed obligations deserves careful scrutiny.

Management fees may be fixed, cost-plus or based on revenue. Each method distributes risk differently. For a percentage fee, model what happens when collections rise but costs rise faster. For cost-plus, define allowable costs and audit rights. For a fixed fee, specify service levels and remedies for repeated failures. Review termination rights, transition assistance and data access.

State rules differ, and corporate-practice restrictions may affect ownership and control arrangements. A generic transaction diagram is not a substitute for state-specific advice. Ask healthcare counsel to trace the agreements and identify which decisions must remain with licensed clinicians. Then review the actual operating model with physician leaders, because nominal authority can be undermined by budgets, staffing rules or contract provisions that make independent decisions difficult.

4. Normalize earnings before discussing a multiple

Buyers and sellers often disagree first about earnings, not the multiple. Normalize the practice using consistent financial statements and supporting data. Separate owner compensation for clinical work from distributions, identify personal or one-time expenses, review related-party rent, and reconcile billed charges, collections, contractual adjustments and bad debt. Include the cost of replacing an owner's administrative responsibilities if the practice would need a new manager after closing.

Adjusted EBITDA is a negotiated measure, not a standardized cash balance. Scrutinize every proposed add-back: a genuine one-time expense may be reasonable, while recurring recruiting, technology, travel, management or facility costs are part of operating the business. Ask the buyer to show the calculation by general-ledger account and provide the same definition for the platform and future add-ons. If the buyer relies on a different accounting convention after close, understand whether it can change the metric used for earnouts or equity distributions.

A higher multiple on overstated earnings can produce less value than a lower multiple on a well-supported figure with fewer contingent terms. Prepare a quality-of-earnings package before exclusivity. Reconcile provider production, payer mix, staffing costs and capital needs. Explain unusual results with source records. Clean data can reduce diligence friction and help owners compare bids.

5. Rollover equity: what is actually retained

Rollover equity is the portion of a seller's proceeds reinvested into the buyer or a related holding company. It can align the seller with future growth and create additional proceeds if the platform succeeds. It can also concentrate risk in a private security with limited information rights or restricted resale. A percentage of "equity" does not tell you what share of proceeds you will receive at exit.

Request the full capitalization table on a fully diluted basis, including sponsor ownership, management incentives, preferred interests and debt. Obtain the distribution waterfall. Understand whether preferred investors receive their capital plus a return before common holders receive proceeds, and how transaction costs and management incentives are treated. Ask for worked examples at a low exit value and no sale. Require the examples to show proceeds to your specific security class.

An illustrative scenario: an owner rolls $2 million into a new entity and is shown a model in which that interest could be worth $4 million after a later sale. Those amounts are illustrative, not a forecast. The later value depends on the owner's percentage after dilution, the company's debt, preferred claims, the exit price, transaction expenses and the timing of any liquidity event. Ask who can issue new equity, incur debt, make distributions, sell assets or approve a recapitalization. Determine whether you have information rights and what happens to the rollover if you leave employment, become disabled or disagree with management.

The rollover may also receive a different security class from the sponsor's investment. It may be nonvoting, subordinated or subject to transfer restrictions. If owners must sell their interest alongside the sponsor, understand drag-along rights and the treatment of representations, indemnities and escrow. If a sponsor can sell without your consent, clarify whether you can participate and on what terms. Have tax counsel review whether the rollover qualifies for intended tax treatment and what happens if the transaction changes before closing.

6. Separate purchase consideration from future work

A proposal may combine cash at close, rollover equity, a seller note and an earnout. These amounts are not interchangeable. Cash is subject to closing adjustments. A note creates repayment risk. An earnout depends on defined results and the buyer's decisions. Employment compensation pays for post-close services. One headline number hides the differences in certainty and timing.

A useful comparison lists gross consideration, debt payoff, expenses, working-capital adjustments and net cash proceeds. Beside that, show contingent proceeds under several outcomes. Negotiate the earnout metric, period, accounting policies, reporting access and dispute procedure. Consider whether the buyer could change staffing or management fees in ways that affect the metric.

Employment terms deserve their own review. Compare the post-close compensation formula with historical earnings for equivalent clinical work. Define productivity measures, supervision duties, administrative time and work location. Clarify who may alter the schedule. If leadership responsibilities are expected, specify authority and how that role can be removed.

7. Governance and integration

The control discussion should be concrete. Ask what decisions owners retain over clinical policies, staffing, payer participation and budgets. Distinguish matters controlled by the professional entity from decisions controlled by the MSO or parent. Identify approval thresholds and deadlock procedures. A promise that physicians "remain in charge of care" does not explain how to address a budget that leaves too few staff.

Integration can improve billing or cybersecurity. It can also disrupt local systems. Request a plan covering the electronic record and payroll. Name accountable leaders and milestones. Determine which costs the platform pays. Set a process for correcting data conversion or payment problems.

The evidence base does not establish a single causal story for every dermatology transaction. Research has reported changes in selected prices and volume measures, with variation by study and specialty. Those measures are not a direct evaluation of your practice's quality or owner experience. Use the evidence to ask operational questions: what will change, how will it be measured, and who can intervene if the change harms capacity or service continuity?

8. Alternatives and transaction readiness

A sale is one route to liquidity and succession. Owners may also consider internal succession, a physician partnership or a staged transition. Each path affects control and workload differently. Evaluate the practical alternative honestly. A buyer's offer looks different when owners have a credible plan for leadership transition.

Before contacting buyers, resolve shareholder questions: who wants liquidity, who will remain and whether owners have different time horizons. Review buy-sell agreements and change-of-control clauses. Prepare clean financial and compliance records. Establish a process for confidentiality and access to sensitive information. A single early conversation can limit bargaining power if owners are unprepared.

Owner implications

Owners should judge a proposal by how certain its value is and whether it fits their goals. Translate the offer into net proceeds, continuing obligations and equity outcomes under several cases. Identify which outcomes depend on buyer discretion. A transaction can provide valuable liquidity while transferring decisions that matter deeply to the physicians who built the practice.

No public figure can tell an individual owner the right multiple or rollover percentage. Terms depend on local competition, earnings quality and the capital structure. Compare at least one alternative to a sale. Decide in advance which rights are essential and what would cause you to stop the process.

Action checklist

• Align owners on liquidity goals, clinical commitments and leadership transition.
• Reconcile earnings, owner compensation, add-backs, working capital and capital needs.
• Prepare provider and payer schedules, then check the locations separately.
• Diagram the clinical entity and MSO. Attach the management agreements.
• Confirm the management fee, covered services, audit rights and termination mechanics.
• Record cash and escrow separately. Itemize rollover and employment pay, with the earnout on its own line.
• Obtain the fully diluted capitalization table and modeled distribution waterfall.
• Stress-test rollover value for debt, dilution, lower exit values and no liquidity event.
• Review governance, clinical authority, budget rights, information rights and transfer terms.
• Define earnout calculations, accounting rules, access to records and dispute resolution.
• Compare post-close compensation and duties with the current owner arrangement.
• Ask for the platform's integration plan, operating evidence and accountable executives.
• Have independent healthcare counsel review the state-specific documents.
• Preserve a credible succession or operating alternative while evaluating bids.

Sources

• Tan S, Seiger K, Raza F, et al. "Trends in Private Equity Acquisition of Dermatology Practices in the United States." JAMA Dermatology.
• Kannan S, Bruch JD, Song Z. "Private Equity Acquisitions of Physician Medical Groups Across Specialties." JAMA.
• Singh Y, Song Z, Polsky D, et al. "Association of Private Equity Acquisition of Physician Practices With Changes in Health Care Spending and Utilization." JAMA Health Forum.
• Braun RT, Bond AM, Qian Y, et al. Study of PE effects on dermatology prices and spending. Health Affairs.
• CMS. National Health Expenditure Data: Fact Sheet.

Scope and limitations

This paper addresses transaction structures and business considerations for owners of US dermatology practices. It is educational and does not evaluate a particular buyer, deal, valuation, tax position or state-specific legal arrangement. The research figures come from defined samples and methods; they do not represent a complete transaction registry and should not be treated as forecasts. Public transaction announcements rarely disclose complete economics, and private agreements vary substantially. Owners should obtain independent professional advice based on the entities, state law, financial records and proposed documents relevant to their circumstances.

Questions? Contact Richard@DoctorsInvestorClub.com.

Educational information only. This paper is not legal, tax, financial, investment or professional advice. It provides no clinical or patient advice.

Related resources

• Owner Resource Library
• Practice valuation calculator
• Owner guides